US · PASG
Passage Bio, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Philadelphia, PA 19103
- Website
- passagebio.com
Price · as of 2024-12-31
$4.97
Market cap 28.99M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $404.00 | ||||
| 2020 | $427.20 | ||||
| 2021 | $59.00 | ||||
| 2022 | $23.00 | ||||
| 2023 | $29.00 | ||||
| 2024 | $9.20 |
AI valuation
Our deep-learning model estimates Passage Bio, Inc.'s (PASG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $4.97
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PASG | Passage Bio, Inc. | $4.97 | 28.99M | — | — | — | — | -0.43 | 0.45 | — | 0.38 | — | 0.45 | 0.00% | — | — | -75.07% | -423.28% | -51.21% | 0.42 | — | 4.07 | 3.96 | 0.19 | -4250.00% | — | -3880.00% | -172.71% | -2.48 | -288.54% | 0.00% | 0.00% | 60.04% | 0.33 | 0.49 | — | -10.18 |
| ALLR | Allarity Therapeutics, In… | $0.97 | 15.6M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| CASI | CASI Pharmaceuticals, Inc… | $0.21 | 3.21M | +5,727% | +324% | — | +8,512% | -0.86 | 18.23 | 1.18 | -1.14 | -3.22 | 20.92 | 39.06% | -138.84% | -137.57% | -301.80% | -351.62% | -60.89% | 11.96 | -45.49 | 1.09 | 0.86 | -0.25 | 2673.00% | -1577.00% | 3267.00% | -87.31% | -0.80 | -261.48% | 2.13% | -1.80% | 2.13% | -1.00 | -1.35 | 1.39 | -19.70 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLGN | CollPlant Biotechnologies… | $0.57 | 7.18M | +8,539% | +137% | — | +21,233% | -2.30 | 2.84 | 74.26 | -1.89 | -1.72 | 2.87 | -417.09% | -3349.71% | -3225.05% | -79.46% | -364.64% | -62.87% | 0.23 | -1014.76 | 4.44 | 4.21 | 0.57 | 13387.00% | -9530.00% | 29214.00% | -38.11% | -4.75 | -308.10% | 0.00% | 0.00% | 0.00% | -1.71 | -2.02 | 57.12 | -6.47 |
| ENLV | Enlivex Therapeutics Ltd. | $1.15 | 27.95M | — | — | — | — | -1.63 | 1.03 | — | -0.09 | — | 1.03 | 0.00% | — | — | -55.95% | -720.93% | -46.54% | 0.02 | -1195.08 | 6.84 | 6.56 | 0.19 | -5321.00% | — | -4482.00% | -53.71% | -3.42 | -608.40% | 0.00% | 0.00% | 12.23% | -0.09 | -0.10 | — | -3.74 |
| GDTC | CytoMed Therapeutics Limi… | $1.08 | 12.67M | +4,473% | +13% | — | +965% | -16.97 | 4.76 | 601.35 | -15.62 | — | 4.81 | 100.72% | -5049.84% | -3621.15% | -24.43% | -98.92% | -22.01% | 0.05 | -172.79 | 9.89 | 8.22 | 1.84 | -4483.00% | -8210.00% | 1064.00% | -9.62% | -4.47 | -113.37% | 0.00% | 0.00% | 0.00% | -10.65 | -9.29 | 537.89 | 22.44 |
| LSTA | Lisata Therapeutics, Inc. | $4.10 | 36.16M | — | -69% | — | — | -0.98 | 0.66 | 19.66 | 0.52 | — | 0.67 | 100.00% | -2240.90% | -1998.50% | -51.43% | 1147.42% | -44.56% | 0.00 | — | 6.16 | 5.73 | 0.72 | -698.00% | — | -337.00% | -98.47% | -3.45 | 1030.67% | 0.00% | 0.00% | 0.00% | 0.51 | 0.59 | -11.45 | -20.94 |
| MTVA | MetaVia Inc. | $1.51 | 3.32M | — | — | — | — | -0.44 | 1.52 | — | 0.13 | -0.97 | 1.52 | 0.00% | — | — | -224.18% | 426.89% | -141.35% | 0.02 | — | 1.94 | 1.94 | 0.55 | 4472.00% | — | 12784.00% | -205.58% | -2.99 | 366.27% | 0.00% | 0.00% | 0.00% | 0.13 | 0.16 | — | -16.10 |
| NCNA | NuCana plc | $2.16 | 13.12M | — | — | — | — | -41.51 | 132.44 | — | -34.78 | — | 210.00 | 0.00% | — | — | -182.30% | 1515.50% | -89.22% | 0.03 | — | 1.42 | 1.31 | 0.29 | -3771.00% | — | -2789.00% | -2.46% | -2.21 | 1524.22% | 0.00% | 0.00% | 0.00% | -34.28 | -40.29 | — | 27.59 |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
- CEO
- William Chou
- Employees
- 60
- Beta
- 1.73
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $4.97) − 1 = — (DCF, example).